Clinical Trial Update: A Dose-ranging Study for SPM 962 in Parkinson's Disease Patients [Phase 2]

View source ↗

Summary

A Phase 2 dose-ranging trial of SPM 962 in Parkinson's disease has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• SPM 962

Snippet

Sponsor: Otsuka Pharmaceutical Co., Ltd. | Conditions: Parkinson's Disease | Phase 2 | Status: COMPLETED | Results posted: 2014-03-19